The short answer
Vitamin E and pentoxifylline have been used together under medical supervision. Added bleeding risk is uncertain, so review the dose and other medicines rather than stopping a prescribed combination automatically.
What this answer covers
Oral vitamin E supplements with oral extended-release pentoxifylline. Supervised post-radiation regimens, food intake and other high-dose supplement uses are distinct.
- Supplement or preparation
- Vitamin E
- Medication ingredient
- pentoxifylline
The combination has been used deliberately
A small randomized trial after breast radiation used pentoxifylline 400 mg three times daily plus vitamin E 400 IU daily for six months. Investigators reported good tolerability and studied tissue fibrosis. This counters a blanket claim that the two must never be used together; it does not prove every dose safe.
The trial cannot rule out uncommon bleeding
The registry reports no serious adverse events in either group, but the study was small and used a threshold for reporting other events. Its enrollment and duration differ slightly from the journal report. Neither source was designed to establish a precise rate of rare bleeding for all pentoxifylline users.
High supplement doses still deserve review
NIH guidance notes bleeding concerns with large vitamin E doses and medicines that affect clotting. Pentoxifylline also carries bleeding precautions. Tell your clinician the dose, formulation and any aspirin or anticoagulant use; the evidence does not give a universal safe cutoff for this combination.
Follow the clinician’s intended regimen
If the two were prescribed together after radiation, ask that clinician before changing the plan. If you are adding vitamin E yourself, discuss why it is needed and what monitoring fits your history. A few hours of separation is not an established way to prevent bleeding, and dietary vitamin E is a different exposure from high-dose supplements.
Evidence and practical considerations
Side effects & toxicity
A general increase in bleeding from vitamin E with pentoxifylline has not been established; the combination has also been studied as a supervised treatment.
- Exact scope
- Oral vitamin E supplements with oral extended-release pentoxifylline. Supervised post-radiation regimens, food intake and other high-dose supplement uses are distinct. with Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
- Medication form and route
- Oral
What remains uncertain
- Small post-radiation trial reported tolerability but cannot exclude rare bleeding or establish all doses safe. Registry and publication differ in enrollment and duration; adverse-event reporting threshold limits reassurance.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with intermittent claudication due to chronic occlusive arterial disease.
Bleeding reported with or without NSAIDs, anticoagulants or platelet inhibitors. Prior methylxanthine intolerance, including caffeine, is a contraindication. Pentoxifylline can raise theophylline levels; strong CYP1A2 inhibitors can raise pentoxifylline exposure.
How this applies: Exact drug/formulation guidance. Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
Does not establish an interaction with every supplement, or transfer theophylline effects to caffeine. Occasional hypotension/arrhythmia reports were not more frequent than placebo in controlled trials. Immediate-release adverse-event results differ from extended-release.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 53 women after breast/chest-wall radiation in the publication.
Combination was reported well tolerated; tissue-compliance fibrosis endpoint improved.
How this applies: Interpret exact preparation, comparator and endpoint; no automatic combination causality.
Abstract-only, small single-center trial not powered for rare bleeding. This off-label clinical setting does not establish all doses safe or justify unsupervised supplementation.
Source 3: Original trial registry results
clinicaltrials.gov · Source check Sep 10, 2026
Population: Women treated after breast radiation.
Registry lists zero serious adverse events among 27 at risk in each arm and a 5% threshold for other events.
How this applies: Original investigator results; direct co-use counterevidence with discrepancies explicit.
Registry lists 54 total and seven months whereas publication lists 53 and six months. Do not silently reconcile or infer complete absence of rare bleeding. Small study and reporting threshold limit reassurance.
Source 4: Government nutrient guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Vitamin E supplement users.
High doses may affect clotting and increase bleeding concern with anticoagulant or antiplatelet medicines.
How this applies: General precaution considered alongside direct combination trial counterevidence.
No exact pentoxifylline risk estimate or validated safe cutoff. Original guidance body accessed through captured web open.
Source 5: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
Pentoxifylline, IN.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Side effects & toxicity
Review vitamin E dose and other bleeding-risk medicines with the clinician managing pentoxifylline.
- Exact scope
- Oral vitamin E supplements with oral extended-release pentoxifylline. Supervised post-radiation regimens, food intake and other high-dose supplement uses are distinct. with Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
- Medication form and route
- Oral
What remains uncertain
- Individual assessment rather than blanket prohibition; no universal safe supplement threshold or recommendation to stop a prescribed combination.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with intermittent claudication due to chronic occlusive arterial disease.
Bleeding reported with or without NSAIDs, anticoagulants or platelet inhibitors. Prior methylxanthine intolerance, including caffeine, is a contraindication. Pentoxifylline can raise theophylline levels; strong CYP1A2 inhibitors can raise pentoxifylline exposure.
How this applies: Exact drug/formulation guidance. Exact pentoxifylline RxCUI 8013 IN confirmed by current RxNorm. Oral extended-release 400 mg tablets for intermittent claudication; experimental immediate-release, intravenous and other-drug exposures are distinct.
Does not establish an interaction with every supplement, or transfer theophylline effects to caffeine. Occasional hypotension/arrhythmia reports were not more frequent than placebo in controlled trials. Immediate-release adverse-event results differ from extended-release.
Source 2: Government nutrient guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Vitamin E supplement users.
High doses may affect clotting and increase bleeding concern with anticoagulant or antiplatelet medicines.
How this applies: General precaution considered alongside direct combination trial counterevidence.
No exact pentoxifylline risk estimate or validated safe cutoff. Original guidance body accessed through captured web open.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 53 women after breast/chest-wall radiation in the publication.
Combination was reported well tolerated; tissue-compliance fibrosis endpoint improved.
How this applies: Interpret exact preparation, comparator and endpoint; no automatic combination causality.
Abstract-only, small single-center trial not powered for rare bleeding. This off-label clinical setting does not establish all doses safe or justify unsupervised supplementation.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 0e10c591a260dfd9
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.